Tiglutik Dosage
Generic name: RILUZOLE 50mg in 10mL
Dosage form: oral suspension
Drug class: Miscellaneous central nervous system agents
Medically reviewed by Drugs.com. Last updated on Feb 8, 2024.
Dosage Information
The recommended dosage for TIGLUTIK is 50 mg (10 mL) taken orally or via Percutaneous Endoscopic Gastrostomy tubes (PEG-tubes) twice daily, every 12 hours. TIGLUTIK should be taken at least 1 hour before or 2 hours after a meal.
Monitoring to Assess Safety
Measure serum aminotransferases before and during treatment with TIGLUTIK.
Important Administration Instructions
Gently shake the TIGLUTIK bottle for at least 30 seconds before administration.Gently shake the TIGLUTIK bottle for at least 30 seconds before administration.
TIGLUTIK can be administered by mouth or via percutaneous endoscopic gastrostomy tubes (PEG-tubes). Both silicone and polyurethane PEG tubes can be used.
See the Instructions for Use for further administration details.See the Instructions for Use for further administration details.
Frequently asked questions
More about Tiglutik (riluzole)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Radicava
Radicava (edaravone) is used to treat amyotrophic lateral sclerosis (ALS). Includes Radicava side ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Qalsody
Qalsody (tofersen) is a prescription medicine used to treat amyotrophic lateral sclerosis (ALS) in ...
Relyvrio
Relyvrio (sodium phenylbutyrate and taurursodiol) was a neuroprotective therapy for the treatment ...
Sodium phenylbutyrate/taurursodiol
Sodium phenylbutyrate/taurursodiol systemic is used for amyotrophic lateral sclerosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
